Radiotherapy for local progression in patients with hormone-refractory prostate cancer

International Journal of Urology

Volumn 6, Issue 4, 1999, Pages 187-191

  Furuya, Yuzo ^a,b   Akakura, Koichiro ^a   Akimoto, Susumu ^a   Ichikawa, Tomohiko ^a   Ito, Haruo ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

Endocrine therapy; Prostate cancer; Radiotherapy; Refractory

Indexed keywords

CHLORMADINONE ACETATE; FOSFESTROL; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; JAPAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SURVIVAL RATE; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033507193     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.1999.06442.x     Document Type: Article

References (14)

1. 1 Walsh PC. The natural history of localized prostate cancer: A guide to therapy. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds). Campbell's Urology, 7th edn. WB Saunders, Philadelphia. 1998; 2539-46.
2. 2 Shimazaki J, Isaka S, Akimoto S et al. Mechanism of relapse in prostate cancer. Aktuelle Urol. 1990; 21: 22-4.
3. 3 Catalona WJ, Scott WW. Carcinoma of the prostate. J. Urol. 1978; 119: 1-8.
4. 4 Isaacs JT, Furuya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin. Cancer Biol. 1994; 5: 391-400.
5. 5 Schulze H, Isaacs JT, Senge T. Inability of complete androgen blockade to increase survival of patients with advanced prostate cancer as compared to standard hormonal therapy. J. Urol. 1987; 137: 909-11.
6. 6 Porter AT, Littrup P, Grignon D, Forman J, Montie JE. Radiotherapy and cryotherapy for prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds). Campbell's Urology, 7th edn. WB Saunders, Philadelphia. 1998; 2605-26.
7. 7 Gleason DF, Mellinger GT, The Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974; 111: 58-64.
8. 8 Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
9. 9 Akakura K, Akimoto S, Ohki T, Igarashi T, Murakami S, Shimazaki J. Radiation therapy for prostate cancer confined to pelvis. Int. J. Urol. 1994; 1: 268-72.
10. 10 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457-81.
11. 11 Cox DR. Regression models and life tables. J. R. Stat. Soc. 1972; 34: 187-220.
12. 12 Arai Y, Yoshida O. A heterogeneous pattern of progression in endocrine-treated patients with prostate cancer. Eur. Urol. 1996; 29: 331-6.
13. 13 Kraus PA, Lutton B, Weiss RM, Prosnitz LR. Radiation therapy for local palliative treatment of prostatic cancer. J. Urol. 1972; 108: 612-14.
14. 14 Kawakami S, Kawai T, Yonese J, Yamauchi T, Ishibasi K, Ueda T. Palliative radiotherapy for local progression of hormone refractory stage D2 prostate cancer. Jpn. J. Urol. 1993; 84: 1681-4 (in Japanese).